Table 1.
Characteristics of patients with ANCA-SVV who reached ESRD
| Characteristic | All ANCA-SVV/ESRD | ANCA-SVV/ESRD with available long-term information |
|---|---|---|
| n (%) or mean ± s.d. | n=136 | n=93 |
| Age at diagnosis (years) (± s.d.) | 57 ± 21 | 56 ± 22 |
| Gender, female (%) | 67 (49%) | 47 (51%) |
| Race | ||
| Caucasian | 113 (83%) | 78 (84%) |
| Other | 23 (17%) | 15 (16%) |
| ANCA typea | ||
| PR3 or C-ANCA | 45 (34%) | 35 (39%) |
| MPO- or P-ANCA | 88 (66%) | 55 (61%) |
| Disease category | ||
| WG | 19 (14%) | 14 (15%) |
| MPA | 67 (49%) | 48 (52%) |
| RL | 49 (36%) | 30 (32%) |
| CSS | 1 (1%) | 1 (1%) |
| Organ involvement, ever | ||
| Lung | 63 (46%) | 47 (51%) |
| ENT | 36 (27%) | 26 (28%) |
| Initial treatmentb | ||
| No treatment | 12 (9%) | 6 (7%) |
| Corticosteroids alone | 23 (17%) | 13 (14%) |
| Prednisone + CYC | 96 (72%) | 70 (77%) |
| Other | 2 (2%) | 2 (2%) |
| Age at initiation of ESRD (years) | 58 ± 21 | 57 ± 22 |
| Duration of disease,# months (± s.d.) | 16.6 ± 27.01 | 16.9 ± 28.8 |
| Median | 3.45 | 2.4 |
| IQR | 0.03, 24.01 | 0.0, 24.01 |
| BVAS at diagnosis of ESRD (± s.d.) | 7.75 ± 8.05 | 8.21 ± 8.25 |
ANCA-SVV, antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis; BVAS, Birmingham Vasculitis Activity Score; CSS, Churg–Strauss syndrome; CYC, cyclophosphamide; ENT, ear, nose, and throat; ESRD, end-stage renal disease; MPA, microscopic polyangiitis; RL, renal-limited disease; WG, Wegener's granulomatosis.
Duration of disease before ESRD among patients who reached ESRD and for the full duration of follow-up for the non-ESRD group.
Three patients were reported as 'ANCA positive,' but had missing information on ANCA specificity. These three patients were among those with long-term follow-up information.
Three patients had missing information on initial treatment, two of whom were among those with long-term follow-up information.